Loading cancer entity…
Loading cancer entity…
Clinical trials
3,385 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00545519 | A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Apr 23, 2013 | clinicaltrials |
| NCT01268774 | Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide. | completed | — | 529 | LEO PharmaINDUSTRY | 0 | Apr 18, 2013 | clinicaltrials |
| NCT00440635 | Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma | completed | — | 641 | Janssen-Cilag International NVINDUSTRY | 0 | Apr 16, 2013 | clinicaltrials |
| NCT01829412 | Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple Myeloma(MMY-MRI-08) | completed | N/A | 50 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Apr 11, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT00303797 | Sorafenib and Bortezomib in Treating Patients With Advanced Cancer | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00996957 | Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 37 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01025206 | A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma | completed | Phase 1 | 35 | BioInvent International ABINDUSTRY | 4 | Mar 15, 2013 | clinicaltrials |
| NCT01148108 | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | completed | Phase 2 | 14 | TelikINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01536145 | CP-751,871 Treatment For Patients With Multiple Myeloma | completed | Phase 1 | 47 | PfizerINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01030302 | A Retreatment Study With Bortezomib for Multiple Myeloma | completed | — | 56 | Janssen Korea, Ltd., KoreaINDUSTRY | 0 | Mar 8, 2013 | clinicaltrials |
| NCT00661544 | Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00536575 | Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 13 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2013 | clinicaltrials |
| NCT01396200 | Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine | completed | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 26, 2013 | clinicaltrials |
| NCT01005628 | Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) | completed | — | 1,121 | Janssen Korea, Ltd., KoreaINDUSTRY | 1 | Feb 20, 2013 | clinicaltrials |
| NCT01074060 | Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00428545 | Bevacizumab and Bortezomib in Patients With Advanced Malignancy | completed | Phase 1 | 104 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00310024 | Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00062621 | Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure | completed | Phase 1 | 5 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00401804 | Bortezomib-Dexamethasone-Doxorubicin-Study | completed | Phase 2 | 72 | Austrian Forum Against CancerOTHER | 2 | Jan 24, 2013 | clinicaltrials |
| NCT00028821 | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00047203 | Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00003166 | Bryostatin and Vincristine in B-Cell Malignancies | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00335348 | Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse | completed | Phase 2 | 101 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00118170 | Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | completed | Phase 1 | 150 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00124605 | Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00253578 | Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00882063 | Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 19 | Piramal Enterprises LimitedINDUSTRY | 1 | Nov 21, 2012 | clinicaltrials |
| NCT00513175 | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | completed | — | 44 | University of California, San FranciscoOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00012350 | Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma | completed | Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 23, 2012 | clinicaltrials |
| NCT00920855 | Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | CephalonINDUSTRY | 1 | Oct 4, 2012 | clinicaltrials |
| NCT01700608 | Prospective Observational Study on Plerixafor After Chemotherapy | completed | — | 27 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 4, 2012 | clinicaltrials |
| NCT00005624 | CI-994 in Treating Patients With Advanced Myeloma | completed | Phase 2 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 25, 2012 | clinicaltrials |
| NCT01198457 | Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment(BONA) | completed | — | 147 | BayerINDUSTRY | 1 | Sep 7, 2012 | clinicaltrials |
| NCT00710528 | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 192 | Gilead SciencesINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT00146055 | Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | completed | Phase 2 | 60 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00067639 | Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00303199 | Study of ZIO-101 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 35 | Alaunos TherapeuticsINDUSTRY | 2 | Jul 19, 2012 | clinicaltrials |
| NCT00592046 | A Phase I Trial of ZIO-101 in Hematologic Cancers | completed | Phase 1 | 12 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 19, 2012 | clinicaltrials |
| NCT00476294 | Long-Term Follow Up Study for AMD3100 Patients | completed | — | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 11, 2012 | clinicaltrials |
| NCT00415064 | Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma | completed | Phase 1 | 32 | AEterna ZentarisINDUSTRY | 1 | Jul 6, 2012 | clinicaltrials |
| NCT00925821 | Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 146 | Wuerzburg University HospitalOTHER | 1 | Jun 28, 2012 | clinicaltrials |
| NCT00660166 | Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions | completed | Phase 1 | 13 | Tufts Medical CenterOTHER | 1 | Jun 27, 2012 | clinicaltrials |
| NCT01524445 | Retrospective Survey of Re-treatment With Bortezomib | completed | — | 35 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 1 | Jun 12, 2012 | clinicaltrials |
| NCT00427557 | Cellular Therapy With Cord Blood Cells | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2012 | clinicaltrials |
| NCT00420849 | A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 587 | Celgene CorporationINDUSTRY | 5 | May 21, 2012 | clinicaltrials |
| NCT00234169 | A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone | completed | Phase 1 / Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 10, 2012 | clinicaltrials |
| NCT00089453 | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant | completed | Phase 1 | 10 | University of ArkansasOTHER | 1 | Apr 19, 2012 | clinicaltrials |
| NCT01006070 | Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine | completed | — | 50 | University of California, San FranciscoOTHER | 1 | Mar 21, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Apr 23, 2013source: clinicaltrials